✦ LIBER ✦

Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial

✍ Scribed by Eli D. Ehrenpreis; Sunanda V. Kane; Lawrence B. Cohen; Russell D. Cohen; Stephen B. Hanauer

Book ID: 118521873
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 179 KB
Volume: 117
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(99)70276-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Open label trial of clarithromycin thera

Open label trial of clarithromycin therapy in Japanese patients with Crohn’s disease

✍ Satoko Inoue; Hiroshi Nakase; Minoru Matsuura; Satoru Ueno; Norimitsu Uza; Hiros 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

Thalidomide for the treatment of refract

Thalidomide for the treatment of refractory radiculopathic pain: An open label trial

✍ A. Chagnon 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 46 KB

P.16.17 THALIDOMIDE THERAPY FOR PATIENTS

P.16.17 THALIDOMIDE THERAPY FOR PATIENTS WITH ANTI-TNF REFRACTORY/INTOLERANT CROHN'S DISEASE

✍ M.L. Scribano; L. Cantoro; C. Prantera; A. Kohn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Extracorporeal photopheresis for the tre

Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study

✍ Maria T. Abreu; Christian von Tirpitz; Robert Hardi; Martin Kaatz; Gert Van Assc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 2 views

## Background: Extracorporeal photopheresis (ecp) is effective in immune-mediated disorders. a prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ecp in patients with active crohn's disease (cd) who were refractory to or intolerant of immunosuppressants and/o

An open-label pilot study of low-dose th

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease

✍ Eric A. Vasiliauskas; Lori Y. Kam; Maria T. Abreu-Martin; Philip V. Hassard; Kos 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Increases in body mass index during infl

Increases in body mass index during infliximab therapy in patients with Crohn’s disease: An open label prospective study

✍ Maki Nakahigashi; Takayuki Yamamoto 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 410 KB